ARTICLE | Clinical News
P2B001: Completed Phase IIb enrollment
March 9, 2015 7:00 AM UTC
Pharma Two completed enrollment of 149 patients in a double-blind, placebo-controlled, U.S. and Israeli Phase IIb trial evaluating 2 doses of oral P2B001 once daily for 12 weeks. The company is develo...